Vomaris Innovations, an electroceutical company specialising in microcurrent-generating solutions for the wound care market, has entered into an exclusive partnership for its Procellera antimicrobial wound dressings with Arthrex Inc.
Procellera is powered by wireless advanced microcurrent technology, and offers a new generation solution for wound and incisional care with demonstrated broad-spectrum antimicrobial and anti-biofilm efficacy, and the ability to accelerate cellular migration for enhanced wound healing.
“The Procellera product is the perfect finishing touch to our orthopaedic procedures. Shoulder and knee arthroscopy and arthroplasty, and foot and ankle procedures all have a risk of infection that can greatly inhibit a patient’s return to normal activity. Expanding the use of products like Procellera with our existing procedures and products will have a positive impact on patient safety and health economics for our clients. This product aligns well with our goal to help our surgeons treat their patients better,” said David Shepard, orthobiologics director of Arthrex.
Under the terms of this distribution agreement, Arthrex will have exclusive global distribution rights to Procellera Technology in the orthopaedic and sports medicine markets for both human and veterinary applications. Vomaris will have continued responsibility for manufacturing and ongoing research and development. Responsibilities related to future orthopaedic development programmes utilising Procellera Technology will be shared between both organisations.